Synthesis of (2S,3R,4R)-4,5-Dihydroxyisoleucine and Derivatives
AssigneesHeidelberg Pharma Research GmbH, Corden Pharma International GmbH
InventorsCaroline Knittel, Mary-Ann Siegert, Roderich Süssmuth, Christoph Wink, Gerhard Jas
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for the preparation of a 4,5-dihydroxyisoleucine derivative comprising the steps of asymmetric Claisen rearrangement of a Z-aminocrotyl-glycin ester and subsequent kinetic resolution of the product diastereomer mix by acylase, and subsequent Sharpless dihydroxylation of the resulting 2-amino-3-methylpent-4-enoic acid derivative.
Claims16
A method for the preparation of (2S,3S)-2-aminopent-4-enoic acid (30),
- wherein said method comprises
- a) the Claisen rearrangement step of reacting a Z-crotyl-glycin ester derivative 200
- wherein R2A is an amino protecting group stable under conditions favourable to Claisen rearrangement,
- in the presence of a chiral ligand to yield 2-aminopent-4-enoic acid derivative (300)
- and
- b) an enzymatic resolution step, wherein 2-aminopent-4-enoic acid derivative (310)
- is converted to yield (2S,3S)-2-aminopent-4-enoic acid (30).
An intermediate in a synthesis of (2S,3S)-2-aminopent-4-enoic acid (30) or a derivative thereof, selected from:
- a. [(Z)-but-2-enyl] 2-[(2,2,2-trifluoroacetyl)amino]acetate,
- b. [(Z)-but-2-enyl] 2-[(2,2-difluoroacetyl)amino]acetate,
- c. [(Z)-but-2-enyl] 2-[(2-fluoroacetyl)amino]acetate,
- d. [(Z)-but-2-enyl] 2-(2,2,3,3,3-pentafluoropropanoylamino)acetate
A derivative of (2S,3R)-2-amino-3-methyl-4,5-dihydroxypentanoic acid (430) selected from
- a. (2S,3R)-3-[(2R)-1,4-dioxaspiro[4.5]decan-2-yl]-2-(fluorenylmethyloxycarbonyl amino)butanoic acid;
- b. (2S,3R)-3-[(2R)-6,9-dioxaspiro[4.4]nonan-2-yl]-2-(fluorenylmethyloxycarbonyl amino)butanoic acid;
- c. (2S,3R)-3-[(2R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl]-2-(fluorenylmethyloxycarbonyl amino)butanoic acid;
- d. (2S,3R)-3-[(2R)-4a,8a-dimethoxy-2,3,5,6,7,8-octahydrobenzo[b][1,4]dioxin-3-yl]-2-(fluorenylmethyloxycarbonyl amino)butanoic acid;
- e. (2S,3R)-2-(fluorenylmethyloxycarbonylamino)-3-[(14R)-1,12,13,16-tetraoxadispiro[5.0.5.4]hexadecan-14-yl]butanoic acid;
- f. (2S,3R)-3-[(4R)-2′,7′-dimethylspiro[1,3-dioxolane-2,9′-xanthene]-4-yl]-2-(fluorenylmethyloxycarbonylamino)butanoic acid;
- g. (2S,3R)-3-[(4R)-spiro[1,3-dioxolane-2,9′-xanthene]-4-yl]-2-(fluorenylmethyloxycarbonylamino)butanoic acid;
- h. (2S,3R)-3-[(4R)-2,2-diethyl-1,3-dioxolan-4-yl]-2-(fluorenylmethyloxycarbonylamino)butanoic acid
- i. (2S,3R,4R)-3-methyl-4,5 bis(trimethylsilyl)oxy 2-(fluorenylmethyloxycarbonylamino)butanoic acid
- j. (2S,3R,4R)-3-methyl-4,5 [(1,1-dimethylethyl)dimethylsilyl]oxy 2-(fluorenylmethyloxycarbonylamino)butanoic acid
- k. (2S,3R)-3-[2,2,4,4,-tetramethyl-1,3,5-trioxa-2,4-disiloxylheptane-2yl-] 2-(fluorenylmethyloxycarbonylamino)butanoic acid
- l. (2S,3R)-3-[2,2,4,4,-tetrakis (1-methylethyl)-1,3,5-trioxa-2,4-disiloxylheptane-2yl-] 2-(fluorenylmethyloxycarbonylamino)butanoic acid
Dependencies are inferred from the claim text.